346 related articles for article (PubMed ID: 12352188)
41. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
42. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary.
Wauters CC; Smedts F; Gerrits LG; Bosman FT; Ramaekers FC
Hum Pathol; 1995 Aug; 26(8):852-5. PubMed ID: 7543441
[TBL] [Abstract][Full Text] [Related]
43. MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer.
Rico SD; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; von Leffern I; Heilenkötter U; Jacobsen F; Bernreuther C; Clauditz T; Simon R; Steurer S; Burandt E; Marx AH; Krech T
Pathol Res Pract; 2021 Aug; 224():153533. PubMed ID: 34171599
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women.
Ronnett BM; Shmookler BM; Diener-West M; Sugarbaker PH; Kurman RJ
Int J Gynecol Pathol; 1997 Jan; 16(1):1-9. PubMed ID: 8986525
[TBL] [Abstract][Full Text] [Related]
45. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
46. Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.
Van Rompuy AS; Vanderstichele A; Vergote I; Moerman P
Int J Gynecol Pathol; 2018 May; 37(3):290-295. PubMed ID: 28463910
[TBL] [Abstract][Full Text] [Related]
47. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
48. Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas.
Losi L; Scarselli A; Benatti P; Ponz de Leon M; Roncucci L; Pedroni M; Borghi F; Lamberti I; Rossi G; Marino M; Ponti G; Zangardi G; Menigatti M; Di Gregorio C
Pathol Res Pract; 2004; 200(5):371-7. PubMed ID: 15239345
[TBL] [Abstract][Full Text] [Related]
49. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases.
Lee KR; Young RH
Am J Surg Pathol; 2003 Mar; 27(3):281-92. PubMed ID: 12604884
[TBL] [Abstract][Full Text] [Related]
50. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
Ferreira CR; Carvalho JP; Soares FA; Siqueira SA; Carvalho FM
Int J Gynecol Cancer; 2008; 18(1):59-65. PubMed ID: 17511804
[TBL] [Abstract][Full Text] [Related]
51. [Expression of cytokeratin 7 and 20 in ovarian metastatic carcinomas].
Dai L; Song Q; Li L; Zhong D; Hui Y
Zhonghua Bing Li Xue Za Zhi; 2001 Apr; 30(2):114-7. PubMed ID: 11866966
[TBL] [Abstract][Full Text] [Related]
52. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
Wang F; Yang Y; Du X; Zhu X; Hu Y; Lu C; Sui L; Zhao H; Song K; Yao Q
BMC Cancer; 2023 Jan; 23(1):44. PubMed ID: 36639622
[TBL] [Abstract][Full Text] [Related]
53. Pathology of primary and metastatic mucinous ovarian neoplasms.
Leen SL; Singh N
J Clin Pathol; 2012 Jul; 65(7):591-5. PubMed ID: 22075188
[TBL] [Abstract][Full Text] [Related]
54. Synchronous Ovarian and Appendiceal Mucinous Neoplasms in the Absence of Pseudomyxoma Peritonei.
Gui X; Escobar J; Lee CH; Duggan MA; Köbel M
Int J Gynecol Cancer; 2017 Feb; 27(2):214-222. PubMed ID: 27870702
[TBL] [Abstract][Full Text] [Related]
55. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma.
Shah RN; Badve S; Papreddy K; Schindler S; Laskin WB; Yeldandi AV
Hum Pathol; 2002 Sep; 33(9):915-20. PubMed ID: 12378517
[TBL] [Abstract][Full Text] [Related]
56. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
57. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
58. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.
Rabban JT; Lerwill MF; McCluggage WG; Grenert JP; Zaloudek CJ
Int J Gynecol Pathol; 2009 Jan; 28(1):41-8. PubMed ID: 19047909
[TBL] [Abstract][Full Text] [Related]
59. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features.
McCluggage WG; Wilkinson N
Histopathology; 2005 Sep; 47(3):231-47. PubMed ID: 16115224
[TBL] [Abstract][Full Text] [Related]
60. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification.
Yemelyanova AV; Vang R; Judson K; Wu LS; Ronnett BM
Am J Surg Pathol; 2008 Jan; 32(1):128-38. PubMed ID: 18162780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
